Spyre Therapeutics (SYRE) – Research Analysts’ Weekly Ratings Updates

Spyre Therapeutics (NASDAQ: SYRE) has recently received a number of price target changes and ratings updates:

• 8/26/2026 – Spyre Therapeutics had its price target lowered by Deutsche Bank Aktiengesellschaft from $135.00 to $127.00. They now have a “buy” rating on the stock.
• 8/26/2026 – Spyre Therapeutics had its price target lowered by Wedbush from $130.00 to $123.00. They now have an “outperform” rating on the stock.
• 8/26/2026 – Spyre Therapeutics had its price target lowered by BTIG Research from $132.00 to $121.00. They now have a “buy” rating on the stock.
• 8/16/2026 – Spyre Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/11/2026 – Spyre Therapeutics had its price target raised by BTIG Research from $112.00 to $132.00. They now have a “buy” rating on the stock.
• 8/8/2026 – Spyre Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/5/2026 – Spyre Therapeutics was given a new $120.00 price target by Robert W. Baird.
• 8/5/2026 – Spyre Therapeutics had its price target raised by Wells Fargo & Company from $90.00 to $115.00. They now have an “overweight” rating on the stock.
• 8/5/2026 – Spyre Therapeutics had its price target raised by Wedbush from $100.00 to $130.00. They now have an “outperform” rating on the stock.
• 8/5/2026 – Spyre Therapeutics had its price target raised by Guggenheim from $115.00 to $130.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Spyre Therapeutics was downgraded by Wolfe Research from “outperform” to “peer perform”.
• 7/13/2026 – Spyre Therapeutics had its price target raised by Mizuho from $84.00 to $120.00. They now have an “outperform” rating on the stock.

Insiders Place Their Bets

In other news, CEO Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $95.51, for a total value of $1,432,650.00. Following the completion of the sale, the chief executive officer owned 567,540 shares of the company’s stock, valued at $54,205,745.40. The trade was a 2.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Thomas Henderson sold 20,000 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $100.00, for a total value of $2,000,000.00. Following the completion of the transaction, the director owned 68,606 shares of the company’s stock, valued at $6,860,600. The trade was a 22.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 142,167 shares of company stock valued at $12,779,292. 15.69% of the stock is currently owned by company insiders.

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.